Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid
add-on therapy to improve overall glycemic control in patients with T2DM inadequately
controlled by insulin, with or without concomitant metformin treatment. It was agreed with
PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety
data of vildagliptin especially in Japanese patients when it iwas used on top of insulin.